uniQure (NASDAQ:QURE) Upgraded to Sell at StockNews.com

uniQure (NASDAQ:QURE) was upgraded by equities researchers at StockNews.com to a “sell” rating in a report issued on Wednesday.

QURE has been the topic of a number of other reports. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. The Goldman Sachs Group lifted their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Stifel Nicolaus raised their price objective on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Finally, Cantor Fitzgerald upped their target price on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $40.00.

uniQure Stock Up 1.4 %

NASDAQ:QURE traded up $0.22 during trading hours on Wednesday, reaching $16.13. The company’s stock had a trading volume of 959,066 shares, compared to its average volume of 1,093,868. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market capitalization of $786.18 million, a P/E ratio of -3.25 and a beta of 0.39. The stock has a 50 day moving average price of $14.29 and a two-hundred day moving average price of $9.09. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. Equities analysts predict that uniQure will post -3.75 EPS for the current fiscal year.

Insider Buying and Selling at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QURE. abrdn plc grew its position in uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the period. Franklin Resources Inc. purchased a new stake in shares of uniQure in the third quarter worth about $7,360,000. Point72 Asset Management L.P. grew its holdings in uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after acquiring an additional 752,889 shares during the period. FMR LLC raised its position in uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after acquiring an additional 346,274 shares in the last quarter. Finally, Privium Fund Management B.V. raised its position in uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after acquiring an additional 104,500 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.